The recent trading activity of Roger Jeffs, Chief Executive Officer of Liquidia Corp (NASDAQ:LQDA), introduces an element of executive selling into the discussion surrounding the biopharmaceutical company. Between May 21 and May 26, 2026, Mr. Jeffs sold a total of 75,000 shares of common stock. These dispositions accounted for an aggregate value estimated at $4.58 million.
The sales were structured across three distinct transactions: on May 21, he disposed of 25,000 shares with a volume-weighted average price of $61.1264; the following day, May 22, saw the sale of another 25,000 shares at an average price of $61.5222; and the final transaction occurred on May 26, involving the disposition of 25,000 shares with a volume-weighted average price of $60.3784.
The prices at which these shares were sold exhibited a range, from a low point of $59.16 up to $62.30 per share across the three days. Crucially, all of these sales were executed under the framework of a Rule 10b5-1 trading plan that Mr. Jeffs had adopted on November 5, 2025.
The shares sold during this period were held indirectly through Serendipity BioPharma LLC, an entity where Mr. Jeffs acts as a manager and holds sole voting and dispositive power over the stock. Following these transactions, his direct holdings of Liquidia Corp common stock amount to 1,137,508 shares, which include various tranches of unvested restricted stock units (RSUs). Furthermore, he maintains indirect ownership through two other channels: 46,595 shares via the Roger A. Jeffs Living Trust, where he serves as trustee, and an additional 1,048,095 shares through Serendipity BioPharma LLC.
While the executive sales were recorded, external analysis of Liquidia Corp suggests a highly positive operational environment. The company's stock is currently trading near its 52-week high of $62.30, reflecting a substantial return of 292% over the past year. At the time of reporting, the stock had closed at $60.09, translating to a market capitalization of $5.35 billion for the biopharma firm.
Despite the strong rally and the recent selling activity, one analysis noted that the stock remains undervalued based on current levels. This assessment was backed by Liquidia's financial health score, which received a